title: [Developments in gene delivery vectors for ocular gene therapy].
abstract: Gene therapy is quickly becoming a reality applicable in the clinic for inherited retinal diseases. Its remarkable success in safety and efficacy, in clinical trials for Leber's congenital amaurosis (LCA) type II generated significant interest and opened up possibilities for a new era of retinal gene therapies. Success in these clinical trials was mainly due to the favorable characteristics of the retina as a target organ. The eye offers several advantages as it is readily accessible and has some degree of immune privilege making it suitable for application of viral vectors. The viral vectors most frequently used for retinal gene delivery are lentivirus, adenovirus and adeno-associated virus (AAV). Here we will discuss the use of these viral vectors in retinal gene delivery with a strong focus on favorable properties of AAV. Thanks to its small size, AAV diffuses well in the inter-neural matrix making it suitable for applications in neural retina. Building on this initial clinical success with LCA II, we have now many opportunities to extend this proof-of-concept to other retinal diseases using AAV as a vector. This article will discuss what are some of the most imminent cellular targets for such therapies and the AAV toolkit that has been built to target these cells successfully. We will also discuss some of the challenges that we face in translating AAV-based gene therapies to the clinic.
authors.affiliation: Inserm UMR S968, Institut de la vision, 17, rue Moreau, 75012 Paris, France - Sorbonne universités, UPMC université Paris 6, UMR S968, 75012 Paris, France - CNRS, UMR 7210, 75012 Paris, France.
authors.forename: Hanen
authors.initials: H
authors.lastname: Khabou
authors.affiliation: Inserm UMR S968, Institut de la vision, 17, rue Moreau, 75012 Paris, France - Sorbonne universités, UPMC université Paris 6, UMR S968, 75012 Paris, France - CNRS, UMR 7210, 75012 Paris, France.
authors.forename: Deniz
authors.initials: D
authors.lastname: Dalkara
mesh_terms: D000256:Adenoviridae / Q000235:genetics / Q000502:physiology; D000818:Animals; D002213:Capsid; D004279:DNA, Viral / Q000235:genetics; D000229:Dependovirus / Q000235:genetics / Q000502:physiology; D019020:Directed Molecular Evolution; D005128:Eye Diseases / Q000235:genetics / Q000628:therapy*; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D006801:Humans; D056965:Injections, Intraocular; D016086:Lentivirus / Q000235:genetics / Q000502:physiology; D051379:Mice; D016254:Mutagenesis, Insertional; D016297:Mutagenesis, Site-Directed; D011323:Primates; D012367:RNA, Viral / Q000235:genetics; D011991:Receptors, Virus / Q000502:physiology; D012160:Retina / Q000648:ultrastructure; D014161:Transduction, Genetic; D019076:Transgenes; D057170:Translational Research, Biomedical; D056189:Viral Tropism
chemical_list: D004279:DNA, Viral; D012367:RNA, Viral; D011991:Receptors, Virus